Skip to main content
Important notice

Labour dispute at Canada Post

We have put in place measures to mitigate the impact on our clients.

Important information

The contents of this webpage are in French only.

Find out whether a drug is covered

Over 8,000 prescription drugs are covered under the Public Prescription Drug Insurance Plan. They are included on a regularly updated list. Other drugs not on the list may also be covered on an exceptional basis.

Prescription drug search

Disclaimer : Search results do not have the same value as a legal document. To access the relevant legal document, please refer to the List of Medications.

Apo-Deferasirox (Type J)

Covered
  • Active ingredient(s):
  • Manufactured by:
    Apotex Inc. (Apotex)
  • Strength and dosage form:
    • Tablet 180 mg DIN : 2485273
    • Tablet 360 mg DIN : 2485281
    • Tablet 90 mg DIN : 2485265

pms-Deferasirox (Type J)

Covered
  • Active ingredient(s):
  • Manufactured by:
    Pharmascience Inc. (Phmscience)
  • Strength and dosage form:
    • Tablet 180 mg DIN : 2528304
    • Tablet 360 mg DIN : 2528312
    • Tablet 90 mg DIN : 2528290

Sandoz Deferasirox (Type J)

Covered
  • Active ingredient(s):
  • Manufactured by:
    Sandoz Canada Inc (Sandoz)
  • Strength and dosage form:
    • Tablet 180 mg DIN : 2489902
    • Tablet 360 mg DIN : 2489910
    • Tablet 90 mg DIN : 2489899

Apo-Deferasirox

Covered
  • Active ingredient(s):
  • Manufactured by:
    Apotex Inc. (Apotex)
  • Strength and dosage form:
    • Dispersible Tablet 125 mg DIN : 2461544
    • Dispersible Tablet 250 mg DIN : 2461552
    • Dispersible Tablet 500 mg DIN : 2461560

Sandoz Deferasirox

Covered
  • Active ingredient(s):
  • Manufactured by:
    Sandoz Canada Inc (Sandoz)
  • Strength and dosage form:
    • Dispersible Tablet 125 mg DIN : 2464454
    • Dispersible Tablet 250 mg DIN : 2464462
    • Dispersible Tablet 500 mg DIN : 2464470

How did we do?

Was the information on this page useful to you?
Do not include any personal information. You will not receive any reply.